IONS Long Put Strategy
IONS (Ionis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc.
IONS (Ionis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $13.42B, a beta of 0.37 versus the broader market, a 52-week range of 39.37-86.74, average daily share volume of 1.8M, a public-listing history dating back to 1991, approximately 1K full-time employees. These structural characteristics shape how IONS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates IONS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on IONS?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current IONS snapshot
As of June 29, 2026, spot at $80.94, ATM IV 39.60%, IV rank 3.94%, expected move 11.35%. The long put on IONS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this long put structure on IONS specifically: IONS IV at 39.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a IONS long put, with a market-implied 1-standard-deviation move of approximately 11.35% (roughly $9.19 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IONS expiries trade a higher absolute premium for lower per-day decay. Position sizing on IONS should anchor to the underlying notional of $80.94 per share and to the trader's directional view on IONS stock.
IONS long put setup
The IONS long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IONS near $80.94, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IONS chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IONS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $80.00 | $2.05 |
IONS long put risk and reward
- Net Premium / Debit
- -$205.00
- Max Profit (per contract)
- $7,794.00
- Max Loss (per contract)
- -$205.00
- Breakeven(s)
- $77.95
- Risk / Reward Ratio
- 38.020
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
IONS long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on IONS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$7,794.00 |
| $17.91 | -77.9% | +$6,004.48 |
| $35.80 | -55.8% | +$4,214.96 |
| $53.70 | -33.7% | +$2,425.45 |
| $71.59 | -11.6% | +$635.93 |
| $89.49 | +10.6% | -$205.00 |
| $107.38 | +32.7% | -$205.00 |
| $125.28 | +54.8% | -$205.00 |
| $143.17 | +76.9% | -$205.00 |
| $161.07 | +99.0% | -$205.00 |
When traders use long put on IONS
Long puts on IONS hedge an existing long IONS stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying IONS exposure being hedged.
IONS thesis for this long put
The market-implied 1-standard-deviation range for IONS extends from approximately $71.75 on the downside to $90.13 on the upside. A IONS long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long IONS position with one put per 100 shares held. Current IONS IV rank near 3.94% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IONS at 39.60%. As a Healthcare name, IONS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IONS-specific events.
IONS long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IONS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IONS alongside the broader basket even when IONS-specific fundamentals are unchanged. Long-premium structures like a long put on IONS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current IONS chain quotes before placing a trade.
Frequently asked questions
- What is a long put on IONS?
- A long put on IONS is the long put strategy applied to IONS (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With IONS stock trading near $80.94, the strikes shown on this page are snapped to the nearest listed IONS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IONS long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the IONS long put priced from the end-of-day chain at a 30-day expiry (ATM IV 39.60%), the computed maximum profit is $7,794.00 per contract and the computed maximum loss is -$205.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IONS long put?
- The breakeven for the IONS long put priced on this page is roughly $77.95 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IONS market-implied 1-standard-deviation expected move is approximately 11.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on IONS?
- Long puts on IONS hedge an existing long IONS stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying IONS exposure being hedged.
- How does current IONS implied volatility affect this long put?
- IONS ATM IV is at 39.60% with IV rank near 3.94%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.